Company intelligence / Profile preview

Nanjing Immunophage Biotech Co., Ltd.

Nanjing, Jiangsu Sheng, Chinaimmunophage.com.cn ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

The company has multiple programs in clinical trials, with IPG1094 (MIF inhibitor) and IPG7236 (CCR8 inhibitor) being the most advanced. IPG7236 has completed Phase I trials with excellent PK profile and no severe adverse events, and Phase II trials are in preparation. IPG1094 received FDA IND approval in 2021.

Therapeutic areas: Metabolic DisordersImmunologyDermatologyHematologyOncologyNeurology
Modalities: Small moleculesLarge moleculesAntibodiesMonoclonal antibodies
Industry: Biotech

Drug pipeline

8 assets

IPG7236

7 more assets in the full pipeline.

Request access →

Partnerships

BioDuro-SundiaGlobal biopharmaceutical companies

Beyond the preview

Go deeper on Nanjing Immunophage Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Immunophage Biotech Co., Ltd..

Explore the full profile